Humacyte Past Earnings Performance
Past criteria checks 0/6
Humacyte has been growing earnings at an average annual rate of 4.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 41.3% per year.
Key information
4.4%
Earnings growth rate
81.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -41.3% |
| Return on equity | -817.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Humacyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -111 | 20 | 75 |
| 30 Sep 23 | 0 | -89 | 20 | 0 |
| 30 Jun 23 | 0 | -89 | 20 | 0 |
| 31 Mar 23 | 1 | -29 | 22 | 0 |
| 31 Dec 22 | 2 | -12 | 23 | 62 |
| 30 Sep 22 | 2 | 34 | 23 | 0 |
| 30 Jun 22 | 2 | 28 | 22 | 0 |
| 31 Mar 22 | 1 | -26 | 22 | 0 |
| 31 Dec 21 | 1 | -26 | 21 | 0 |
| 30 Sep 21 | 1 | -85 | 18 | 0 |
| 30 Jun 21 | 2 | -71 | 16 | 0 |
| 31 Mar 21 | 1 | -69 | 14 | 0 |
| 31 Dec 20 | 1 | -67 | 12 | 0 |
| 31 Dec 19 | 6 | -85 | 16 | 0 |
Quality Earnings: HUMA is currently unprofitable.
Growing Profit Margin: HUMA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HUMA is unprofitable, but has reduced losses over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare HUMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HUMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: HUMA has a negative Return on Equity (-817.78%), as it is currently unprofitable.